LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
Pediatric Cancer
Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer
After phase 1, the study will expand in a second phase to test the efficacy of these drugs at the determine dosage.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Overall Cancer Survival Rates Up Among Adolescents, Young Adults
Cancer survival has improved among adolescents and young adults (AYA), but survival disparities are reported.
Higher Risk for Cancer, Mortality Seen With Pediatric-Onset IBD
Individuals with pediatric-onset inflammatory bowel disease (pIBD) have an increased risk for cancer and mortality.
Less Postoperative Chemotherapy for Pediatric Hepatoblastoma Has No Effect on Disease Control
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
Potential Unintended Consequences of the “Right to Try” Act on the Delivery of Palliative Care to Children With Cancer
Will “cure-seeking behavior” for terminally ill children with cancer interfere with the integrated delivery of palliative care?
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Reducing the Reliance on Opioids for Cancer Pain: Is the Switch to Cannabis a Viable Option?
Articles discussing the use of cannabis as a substitute for opioids highlight the limitations of the existing scientific evidence in the field.
Cancer Death Rates Continue to Decline, but Socioeconomic Gaps Widen
The continuous decline in cancer deaths over the past 25 years was attributed to improvements in screening, treatment.
Next post in General Oncology
